Lisata Therapeutics, Inc. presentation by Dr. David J. Mazzo, Ph.D., President & CEO at the 10th Annual Oncology Innovation Forum Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, certepetide (formerly LSTA1), is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next two years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. View here: https://lnkd.in/dDkhmGte
Sachs Associates’ Post
More Relevant Posts
-
We were involved in several important milestones for Perspective Therapeutics, Inc., a clinical-stage innovative radiopharmaceutical company that’s at the forefront of pioneering advanced cancer treatment. We played a crucial role in negotiating a strategic agreement with Lantheus Holdings, Inc. that encompasses not only equity investment but also co-development options and an expansion of manufacturing capability. We also advised on a $69 million follow-on public offering of equity securities. Read our latest press release here: https://lnkd.in/eXvRbCdG #legalnews #cancertreatment #equityinvestment
-
We were involved in several important milestones for Perspective Therapeutics, Inc., a clinical-stage innovative radiopharmaceutical company that’s at the forefront of pioneering advanced cancer treatment. We played a crucial role in negotiating a strategic agreement with Lantheus Holdings, Inc. that encompasses not only equity investment but also co-development options and an expansion of manufacturing capability. We also advised on a $69 million follow-on public offering of equity securities. Read our latest press release here: https://lnkd.in/eMuaVsQQ #legalnews #cancertreatment #equityinvestment
Hogan Lovells advises Perspective Therapeutics on a series of strategic transactions with Lantheus and a US$69 million follow-on public offering of equity securities
hoganlovells.com
-
We were involved in several important milestones for Perspective Therapeutics, Inc., a clinical-stage innovative radiopharmaceutical company that’s at the forefront of pioneering advanced cancer treatment. We played a crucial role in negotiating a strategic agreement with Lantheus Holdings, Inc. that encompasses not only equity investment but also co-development options and an expansion of manufacturing capability. We also advised on a $69 million follow-on public offering of equity securities. Read our latest press release here: https://lnkd.in/eJFRVRqK #legalnews #cancertreatment #equityinvestment
Hogan Lovells advises Perspective Therapeutics on a series of strategic transactions with Lantheus and a US$69 million follow-on public offering of equity securities
hoganlovells.com
-
Corporate Counsel at Hogan Lovells | M&A | Private Equity | Restructuring | Commercial Law
We were involved in several important milestones for Perspective Therapeutics, Inc., a clinical-stage innovative radiopharmaceutical company that’s at the forefront of pioneering advanced cancer treatment. We played a crucial role in negotiating a strategic agreement with Lantheus Holdings, Inc. that encompasses not only equity investment but also co-development options and an expansion of manufacturing capability. We also advised on a $69 million follow-on public offering of equity securities. Read our latest press release here: https://lnkd.in/eeTBkkjG #legalnews #cancertreatment #equityinvestment
Hogan Lovells advises Perspective Therapeutics on a series of strategic transactions with Lantheus and a US$69 million follow-on public offering of equity securities
hoganlovells.com
-
We were involved in several important milestones for Perspective Therapeutics, Inc., a clinical-stage innovative radiopharmaceutical company that’s at the forefront of pioneering advanced cancer treatment. We played a crucial role in negotiating a strategic agreement with Lantheus Holdings, Inc. that encompasses not only equity investment but also co-development options and an expansion of manufacturing capability. We also advised on a $69 million follow-on public offering of equity securities. Read our latest press release here: https://lnkd.in/eWaWx_9z #legalnews #cancertreatment #equityinvestment
Hogan Lovells advises Perspective Therapeutics on a series of strategic transactions with Lantheus and a US$69 million follow-on public offering of equity securities
hoganlovells.com
-
We were involved in several important milestones for Perspective Therapeutics, Inc., a clinical-stage innovative radiopharmaceutical company that’s at the forefront of pioneering advanced cancer treatment. We played a crucial role in negotiating a strategic agreement with Lantheus Holdings, Inc. that encompasses not only equity investment but also co-development options and an expansion of manufacturing capability. We also advised on a $69 million follow-on public offering of equity securities. Read our latest press release here: https://lnkd.in/enAVDmS4 #legalnews #cancertreatment #equityinvestment
Hogan Lovells advises Perspective Therapeutics on a series of strategic transactions with Lantheus and a US$69 million follow-on public offering of equity securities
hoganlovells.com
-
We were involved in several important milestones for Perspective Therapeutics, Inc., a clinical-stage innovative radiopharmaceutical company that’s at the forefront of pioneering advanced cancer treatment. We played a crucial role in negotiating a strategic agreement with Lantheus Holdings, Inc. that encompasses not only equity investment but also co-development options and an expansion of manufacturing capability. We also advised on a $69 million follow-on public offering of equity securities. Read our latest press release here: https://lnkd.in/ebQc2YJP #legalnews #cancertreatment #equityinvestment
Hogan Lovells advises Perspective Therapeutics on a series of strategic transactions with Lantheus and a US$69 million follow-on public offering of equity securities
hoganlovells.com
-
We were involved in several important milestones for Perspective Therapeutics, Inc., a clinical-stage innovative radiopharmaceutical company that’s at the forefront of pioneering advanced cancer treatment. We played a crucial role in negotiating a strategic agreement with Lantheus Holdings, Inc. that encompasses not only equity investment but also co-development options and an expansion of manufacturing capability. We also advised on a $69 million follow-on public offering of equity securities. Read our latest press release here: https://lnkd.in/dKBCGWUF #legalnews #cancertreatment #equityinvestment
Hogan Lovells advises Perspective Therapeutics on a series of strategic transactions with Lantheus and a US$69 million follow-on public offering of equity securities
hoganlovells.com
-
Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar: The global GEP-NET therapeutics market is further expected to increase by the major drivers such as rising incident population, technological advancements, increased funding for new drug development and clinical trials, increasing awareness among common people, increasing research...
-
We were involved in several important milestones for Perspective Therapeutics, Inc., a clinical-stage innovative radiopharmaceutical company that’s at the forefront of pioneering advanced cancer treatment. We played a crucial role in negotiating a strategic agreement with Lantheus Holdings, Inc. that encompasses not only equity investment but also co-development options and an expansion of manufacturing capability. We also advised on a $69 million follow-on public offering of equity securities. Read our latest press release here: https://lnkd.in/eiPc4GwB #legalnews #cancertreatment #equityinvestment
Hogan Lovells advises Perspective Therapeutics on a series of strategic transactions with Lantheus and a US$69 million follow-on public offering of equity securities
hoganlovells.com
